MDxHealth reported first-quarter revenue of $27.4 million and a pro-forma operating loss of $7.9 million for the period ending in May 2026 [1, 2].
These financial results and the accompanying operational cuts signal a strategic pivot as the company struggles with reimbursement challenges and the costs of previous acquisitions. The shift indicates a move away from diversified testing toward a narrower core business to stem losses.
The company announced it will exit the Resolve UTI testing business [2]. As part of this restructuring, MDxHealth plans to close its laboratory facility located in Plano, Texas [1].
Financial data shows the pro-forma operating loss of $7.9 million [2] is an increase from the prior-year pro-forma operating loss of $4.7 million [2]. The company reported cash adjusted for earn-out payment at $28 million [2].
Management said the current financial state is due to operational losses tied to the ExoDx acquisition and ongoing reimbursement challenges [1, 2]. By exiting the Resolve UTI line, the company aims to concentrate its remaining resources on its primary business operations [1, 2].
An operator said, "Good afternoon, everyone, and welcome to today's MDxHealth First Quarter 2026 Earnings Conference Call."
“MDxHealth reported first-quarter revenue of $27.4 million”
The closure of the Plano facility and the abandonment of the Resolve UTI line suggest that MDxHealth is prioritizing liquidity over growth. By narrowing its operational footprint, the company is attempting to mitigate the financial drag caused by the ExoDx acquisition and a difficult reimbursement environment in the diagnostic sector.
